Literature DB >> 11055609

Bacteriologic outcome of children with cefotaxime- or ceftriaxone-susceptible and -nonsusceptible Streptococcus pneumoniae meningitis.

C Olivier1, R Cohen, P Begué, D Floret.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11055609     DOI： 10.1097/00006454-200010000-00018

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


× No keyword cloud information.
  5 in total

1.  Clinical implication of extended-spectrum cephalosporin nonsusceptibility in Streptococcus pneumoniae meningitis.

Authors:  S-H Choi; J-W Chung; B-N Kim; Y G Kwak; T H Kim; E J Lee; E J Choo; M-H Jeon; M S Lee; I-G Bae; S-R Lee; E H Song; J-B Jun; M-N Kim; S-H Kim; S-O Lee; Y S Kim; J H Woo; S-H Choi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-02       Impact factor: 3.267

Review 2.  Setting and revising antibacterial susceptibility breakpoints.

Authors:  John Turnidge; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

Review 3.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation.

Authors:  E Bingen; C Levy; E Varon; F de La Rocque; M Boucherat; P d'Athis; Y Aujard; R Cohen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-30       Impact factor: 3.267

5.  Reference group choice and antibiotic resistance outcomes.

Authors:  Keith S Kaye; John J Engemann; Essy Mozaffari; Yehuda Carmeli
Journal:  Emerg Infect Dis       Date:  2004-06       Impact factor: 6.883
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.